Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 11/20 | 0.54 |
| ▸ | ACE | P12821 | 11/20 | 0.54 |
| ▸ | CPA1 | P15085 | 9/20 | 0.54 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701132 | 1.00 | MME (0.59) | MMEACE2ACECPA1MMEL1 | |
| SCHEMBL22616430 | 0.88 | MME (0.66) | MMEACEMMEL1ITGB3ITGAV | |
| SCHEMBL1768180 | 0.88 | MME (0.66) | MMEACEMMEL1ITGB3ITGAV | |
| SCHEMBL1768183 | 0.88 | MME (0.66) | MMEACEMMEL1ITGB3ITGAV | |
| SCHEMBL15608113 | 0.84 | MME (0.54) | MMEACE2ACECPA1MMEL1 | |
| SCHEMBL11310430 | 0.84 | MME (0.54) | MMEACE2ACECPA1MMEL1 | |
| SCHEMBL4367118 | 0.82 | CA2 (0.47) | ACE | |
| SCHEMBL5219151 | 0.82 | CA2 (0.47) | ACE | |
| SCHEMBL4363617 | 0.82 | CA2 (0.47) | ACE | |
| SCHEMBL4371582 | 0.82 | CA2 (0.47) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735561-B1 | Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8877786-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2735561-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | Novartis AG (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | MME 1/4885ACE2 12/4885ACE 4/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE2 220/4885ACE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.